Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Richard Pratley Added: 1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more
Author(s): Vlado Perkovic Added: 1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median… View more
Author(s): Harriette Van Spall , Added: 1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of… View more
Author(s): Tatsuya Nakama Added: 1 year ago
LINC 2025 - Outcomes from the GRIFFIN study suggest post-procedural functional flow reserve (FFR) could be a useful predictor of restenosis after drug-coated balloon (DCB) angioplasty for superficial femoral artery (SFA) lesions. Restenosis patients showed significantly lower FFR values than non-restenosis patients, and the study resulted in a good FFR cut-off value of restenosis after DCB… View more
Job title: Associate Professor
Dr Thomas Weber is an Austrian cardiologist. He is Deputy Director of the Cardiology Department at the Klinikum Wels-Grieskirchen, in Wels, Austria.His clinical interests cover interventional cardiology, heart failure and hypertension while his scientific interests are pulsatile hemodynamics, arterial stiffness, vascular aging, 24-hour hemodynamics, heart failure, coronary artery disease,… View more
Added: 2 months ago Source:  Interventional Cardiology Review Journal
Long-term follow-up from the FAMOUS-NSTEMI trial suggests that a fractional flow reserve-guided strategy for managing patients with non-ST-segment elevation myocardial infarction (NSTEMI) does not reduce adverse cardiovascular outcomes compared to standard angiography-guided care.¹MethodologyFAMOUS-NSTEMI was a prospective, randomised, controlled trial that enrolled 350 patients with NSTEMI… View more
Personal History Dr Carolyn Webb is based in London, where she works as a research fellow at the National Heart and Lung Institute. Academic History Carolyn studied physiology as an undergraduate at the University of Otago, New Zealand. Then she went on to obtain her PhD in education at Imperial College London. Career Overview Carolyn Webb is a research fellow at the… View more
Author(s): Thomas Johnson Added: 1 year ago
EuroPCR 25 - Substudy findings from ILUMIEN-IV show that virtual flow reserve was slightly higher after angiography guidance rather than an optical coherence tomography (OCT)-based physiology assessment after percutaneous coronary intervention (PCI) in high-risk angiographic lesions.We are joined by Dr Thomas Johnson (Bristol Heart Institute, Bristol, UK) to discuss findings from a retrospective… View more